cyproheptadine has been researched along with Severe Dengue in 1 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Severe Dengue: A virulent form of dengue characterized by THROMBOCYTOPENIA and an increase in vascular permeability (grades I and II) and distinguished by a positive pain test (e.g., TOURNIQUET PAIN TEST). When accompanied by SHOCK (grades III and IV), it is called dengue shock syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rupatadine was previously shown to reduce endothelial dysfunction in vitro, reduced vascular leak in dengue mouse models and to reduce the extent of pleural effusions and thrombocytopenia in patients with acute dengue." | 9.51 | Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial. ( Dissanayake, H; Gangani, C; Gomes, L; Gunasinghe, D; Idampitiya, D; Jayarathna, G; Jeewandara, C; Mahapatuna, SD; Malavige, GN; Narangoda, E; Ogg, GS; Perera, Y; Prathapan, S; Sahabandu, P; Vimalachandran, V; Wanigatunga, C; Wickramanayake, S; Wijewickrama, A, 2022) |
| "Rupatadine was previously shown to reduce endothelial dysfunction in vitro, reduced vascular leak in dengue mouse models and to reduce the extent of pleural effusions and thrombocytopenia in patients with acute dengue." | 5.51 | Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial. ( Dissanayake, H; Gangani, C; Gomes, L; Gunasinghe, D; Idampitiya, D; Jayarathna, G; Jeewandara, C; Mahapatuna, SD; Malavige, GN; Narangoda, E; Ogg, GS; Perera, Y; Prathapan, S; Sahabandu, P; Vimalachandran, V; Wanigatunga, C; Wickramanayake, S; Wijewickrama, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malavige, GN | 1 |
| Jeewandara, C | 1 |
| Wijewickrama, A | 1 |
| Gunasinghe, D | 1 |
| Mahapatuna, SD | 1 |
| Gangani, C | 1 |
| Vimalachandran, V | 1 |
| Jayarathna, G | 1 |
| Perera, Y | 1 |
| Wanigatunga, C | 1 |
| Dissanayake, H | 1 |
| Prathapan, S | 1 |
| Narangoda, E | 1 |
| Idampitiya, D | 1 |
| Gomes, L | 1 |
| Wickramanayake, S | 1 |
| Sahabandu, P | 1 |
| Ogg, GS | 1 |
1 trial available for cyproheptadine and Severe Dengue
| Article | Year |
|---|---|
Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial.
Topics: Animals; Cyproheptadine; Dengue; Double-Blind Method; Humans; Incidence; Mice; Severe Dengue; Treatm | 2022 |